Meeting
2023 ASCO Annual Meeting
A phase 2 study (DisTinGuish) of DKN-01 in combination with tislelizumab + chemotherapy as first-line (1L) therapy in patients with advanced gastric or GEJ adenocarcinoma (GEA).
Authors
Samuel J Klempner
Mass General Cancer Center, Boston, MA
Samuel J Klempner , Bassam Bassam Sonbol , Zev A. Wainberg , Hope Elizabeth Uronis , Vi Kien Chiu , Aaron James Scott , Syma Iqbal , Mohamedtaki Abdulaziz Tejani , Melissa C Stilian , Mathis Thoma , Michael Kagey , Jason Baum , Cynthia A. Sirard , Rachel A Altura , Jaffer A. Ajani
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer - Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT04363801
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4027)
DOI
10.1200/JCO.2023.41.16_suppl.4027
Abstract #
4027
Poster Bd #
335
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Trial in progress: A phase 2, multicenter, open-label study of DKN-01 in combination with tislelizumab and chemotherapy as 1L therapy in patients with unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ; DisTinGuish).
First Author: Keun-Wook Lee
Poster
2022 ASCO Gastrointestinal Cancers Symposium
DKN-01 and tislelizumab ± chemotherapy as a first-line (1L) and second-line (2L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish Trial.
First Author: Samuel J Klempner
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Zanidatamab + chemotherapy as first-line treatment for HER2-expressing metastatic gastroesophageal adenocarcinoma (mGEA).
First Author: Elena Elimova
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649.
First Author: Kohei Shitara